Kornimate/medical-research-clean huggingface dataset:
artificial intelligence and cancer staging in upper gastrointestinal malignancies

Conditions: Gastrointestinal Cancer

Summary: esophageal and stomach cancers, which constitute cancers of the upper region of the digestive system, are cancers that are frequently observed and unfortunately have a low rate of cured patients. in these cases, the stage of cancer at diagnosis is very important for two reasons; first, the stage of the cancer is directly related to the survival time. secondly, treatment is planned according to the stage. different treatments are applied to patients at different stages. currently, the tnm staging (tumor, lymph node and metastases) system is the accepted one worldwide. despite many advanced technology tools used in staging (computed tomography, magnetic resonance imaging, endoscopic ultrasonography), there are still difficulties in correct staging before surgery or before-after neoadjuvant therapy. artificial intelligence techniques are increasingly used in the field of health, especially in the diagnosis and treatment of cancers. obtaining cancer details in radiological images, which cannot be noticed by the human eye, by analyzing big data with the help of algorithms gave rise to the application area of "radiomics". it is stated that with radiomics, there will be improvements in both the diagnosis and staging of cancers and, accordingly, in the treatment. while there are studies on the use of endoscopic methods with artificial intelligence for the early diagnosis of esophageal cancers, a limited number of studies have been conducted on stage estimation from radiological images. in particular, there are not enough studies on the investigation of changes in tumor size after chemotherapy with artificial intelligence and the estimation of staging. in this study, it was aimed to investigate the predictive efficiency of staging and the accuracy of the algorithm developed with artificial intelligence by processing tomography images in a region where esophageal cancers are endemic as a primary outcome and to evaluate the post-treatment mortality, morbidity rates and complication rates of the patients as a secondary outcome.


Eligibility criteria:
inclusion criteria: 1. being diagnosed with esophageal cancer (adenocarcinoma or squamous cancer) 2. being over 18 years old 3. having a tomography image before or after chemotherapy. 4. giving informed consent to participate in the study. 5. having final pathological staging after surgery. exclusion criteria: 1. previous thoracic surgery. 2. having a recurrent tumor 3. inability to perform clinical staging due to technical reasons 4. drawings cannot be made due to poor tomography quality.
continuous venovenous hemofiltration versus continuous venovenuous hemodialysis

Conditions: Acute Renal Failure

Summary: acute kidney injury is often treated with the use of continuous renal replacement therapy. two commonly used treatments are continuous venvenous hemofiltration (cvvh)and continuous venovenous hemodialysis (cvvhd). cvvh uses convective clearance to remove toxins and solutes from the patients circulation, while cvvhd relies on diffusive clearance to remove these same toxins/solutes. this study will evaluate which of these two methods is more effective at clearing the body of waste/solutes. we hypothesize that renal replacement therapy by either modality (hemodialysis or hemofiltration; cvvhd or cvvh, respectively) using a modern membrane and higher blood flow rates will be associated with similar clearances of both small and middle molecular weight solutes. we further believe that continuous renal replacement therapy using cvvhd will be associated with decreased clotting events and longer hemofilter survival, as well as improved resource utilization (i.e. nursing time, alarms, etc.).


Eligibility criteria:
inclusion criteria: * age 18 or older and able to sign consent (or surrogate). * must have been referred to the inpatient nephrology consult service for evaluation of acute kidney injury (aki). * expected survival of at least 48 hours. exclusion criteria: * hemoglobin \< 8 g/dl * serum potassium ≥6.5 milliequivalents per liter (meq/l) * weight \> 120kg.

Keywords: renal replacement therapy
replace- randomized trial evaluating the use of prothrombin complex concentrate to improve survival in patients with traumatic coagulopathy

Conditions: Coagulopathy; Hemorrhage

Summary: uncontrolled hemorrhage continues to be a significant source of mortality for trauma patients. their condition is further complicated by trauma induced coagulopathy (tic), which makes it more difficult to control bleeding due to coagulation factor deficiency. prothrombin complex concentrate (pcc) is thought to be a promising treatment option. this phase ii clinical trial evaluates the use of 4-factor pcc in addition to standard resuscitation methods compared to standard resuscitation methods alone in patients with tic. patients will be randomized at a 1:1 ratio. the primary endpoint of this trial will be 30 day mortality.


Eligibility criteria:
inclusion criteria: 1. ≥15 years old 2. anticipate giving 4+ units based on revised assessment of bleeding and transfusion score ≥ 2 exclusion criteria: 1. cardiopulmonary resuscitation \> 5 minutes 2. penetrating cranial injury or exposed brain matter 3. anticoagulation treatment 4. transfer patients 5. known pregnancy 6. prisoners
mulligan and proprioceptive neuromuscular fasciliation techiniques in rotator cuff pathology

Conditions: Rotator Cuff Injuries

Summary: the aim of this study is to investigate the effects of mulligan mobilization techniques, mobilization with movement (mwms) and proprioceptive neuromuscular facilitation (pnf) techniques, hold-relax active movement technique, on pain, normal joint range of motion, proprioception, scapular dyskinesia and functional status in individuals with rotator cuff syndrome. a total of 60 people were included in the study: 20 participants in the censervative rehabilitation group (conservative treatment), 20 participants in the treatment a (mulligan mobilization application) group, and 20 participants in the treatment b (pnf application) group. individuals were treated for 5 days for 4 weeks. pain before and after treatment with visual analog scale; joint range of motion with goniometer; with proprioception angle repetition test; scapular dyskinesia with lateral scapular slide test; quality of life with sf-36; shoulder functionality was assessed with the western ontario rotator cuff scale (worc).


Eligibility criteria:
inclusion criteria: * between the ages of 25-75, * diagnosed with rotator cuff syndrome, * patients who did not have any obstacle to the evaluation parameters exclusion criteria: * having had shoulder surgery, * presence of scoliosis, * presence of cardiac pacemaker, * history of recent myocardial infarction, * presence of malignancy, * corticosteroid treatment within the last 3 months

Keywords: rotator cuff injuries mulligan mobilization proprioceptive neuromuscular fascilitation pain functionality quality of life
trans-abdominal fetal pulse oximetry

Conditions: Fetal Hypoxia; Fetal Distress; Fetal Acidemia; Fetal or Neonatal Effect of Complication of Labor

Summary: the raydiant oximetry sensing system (lumerah) is a non-invasive fetal pulse oximeter that measures fetal arterial oxygen saturation using safe, non-invasive, transabdominal near-infrared spectroscopy. lumerah is intended as an adjunct to cardiotocography by detecting decreases in fetal oxygenation.

raydiant oximetry, inc. is developing a novel and non-invasive fetal pulse oximetry device to fundamentally improve how fetuses are monitored during labor. the raydiant oximetry sensing system (lumerah) is a fetal pulse oximeter that measures fetal arterial oxygen saturation using safe, non-invasive, transabdominal near-infrared spectroscopy. lumerah performs its measurements without the requirement for transvaginal placement and its associated risks. lumerah is intended as an adjunct to cardiotocography by detecting fetal oxygen deprivation which is both life-threatening to the fetus and can lead to the irreversibly debilitating consequences of newborn metabolic acidosis. the severe consequences associated with newborn metabolic acidosis and the lack of availability of an effective tool to support its early diagnosis led to the development of lumerah. in this study, women in labor will be simultaneously monitored with proven (previously fda-approved) technology as a "ground truth". these women will be simultaneously monitored with both an external and internal oxygen sensor. obstetric health-care providers are blinded to oximetry data presented by both devices; therefore, clinical decisions regarding interventions are made based on the standard factors, including cardiotocography. the primary efficacy analysis will be performed retrospectively by comparing data of fetal oxygenation displayed and recorded by both devices. results of either the lumerah external sensor or the internal sensor will not be used to guide or alter patient management.

Eligibility criteria:
inclusion criteria: 1. willing and capable to provide informed consent 2. age \> 18 years 3. bmi \< 50 (with no more than 4 cm between maternal skin and fetal skin) 4. gestational age \> 36 weeks 5. singleton pregnancy 6. vertex presentation 7. active labor 8. category i or category ii tracings 9. ruptured amniotic sac with cervical dilation of \>2 cm and a station of -2 or lower exclusion criteria: 1. age \<18 years 2. bmi \> 50 third trimester 3. gestational age \< 36 weeks 4. multiple gestation 5. nonvertex fetal presentation 6. suspected vasa previa 7. latent labor 8. category iii ctg tracing (i.e., need for immediate delivery) 9. fetal anomalies and/or chromosomal disorders 10. chorioamnionitis 11. placenta previa 12. history of hiv, genital herpes, or other infection precluding internal monitoring 13. unable to provide informed consent (e.g., cognitively impaired)
a clinical study to assess preliminary efficacy, safety and tolerability of hh-120 nasal spray in covid-19 patients

Conditions: Coronavirus Disease 2019(COVID-19)

Summary: to evaluate the preliminary efficacy and safety of hh-120 nasal spray in the treatment of asymptomatic or mild covid-19.

during this study, participants will receive hh-120 nasal spray treatment for 6 consecutive days, the efficacy and safety of hh-120 will be assessed throughout the study period based on viral clearance, clinical recovery, illness severity and adverse events.

Eligibility criteria:
inclusion criteria: * 18 to 65 years old. * participants with mild covid-19 with symptom onset≤5 days or asymptomatic covid-19. * participants being able and willing to provide informed consent prior to any study-specific procedure. exclusion criteria: * participants with moderate or severe covid-19. * participants within the pregnancy or breastfeeding period or plan to be pregnant during the study period. * participants requiring oxygen treatment (such as non-invasive ventilation, invasive mechanical ventilation, ecmo, etc.). * participants with nasal disease that is inconvenient or intolerant of nasal spray administration, or cannot use the nasal spray treatment. * participants with comorbid malignancy or with a history of malignancy. * participants with active or uncontrolled systemic autoimmune disease. * insufficient function of key organs. * other reasons considered by the investigator to be unsuitable for the trial.

Keywords: covid-19 treatment
evaluation of gcf and salivary ferritin, alp and mmp-8 levels of individuals with different periodontal diseases

Conditions: Periodontal Diseases

Summary: the aim of this clinical study was to determine the levels of ferritin, alkaline phosphatase and matrix metalloproteinase-8 in the gingival crevicular fluid (gcf) and saliva samples were collected from 60 systemically healthy, non-smoker periodontitis (p group, n = 20), gingivitis (g group, n = 20) and periodontally healthy individuals (s group, n = 20) and all clinical parameters were recorded for all groups at baseline. gcf and serum samplings and clinical records were also repeated at 1st and 3rd months visitsfor only p group. ferritin, mmp8, and alp levels in samples were determined by enzyme-linked immunosorbent assay (elisa).


Eligibility criteria:
inclusion criteria: * systemically healthy * at least twenty permanent teeth in the mouth * non-smoker * no medication for continuous use * those who have not used antibiotics, anti-inflammatory and systemic corticosteroid drugs in the last 6 months. * not in pregnancy or lactation period. * for the periodontitis group that has not received periodontal treatment in the last 6 months * for the periodontitis group; according to the evaluation made in 6 regions of each tooth, individuals with 30% or more bleeding on probing area, at least 2 teeth not adjacent to each quarter jaw with a depth of 5 mm or more and 4 mm or more attachment loss, coronal 1/3 and more on radiography (horizontal and / or vertical) bone loss * for the gingivitis group; according to the evaluation made in 6 regions of each tooth, individuals with 10% or more bleeding on probing area, having a probing depth of less than 4mm and no attachment loss * for healthy group; according to the evaluation made in 6 regions of each tooth,individuals with less than 10% bleeding on probing area, having a probing depth less than 4mm and no loss of attachment were included in the study. exclusion criteria: * any oral or systemic disease * regularly using a systemic medication * during pregnancy or lactation * received periodontal treatment within the last 6 months. * those who received antibiotic, anti-inflammatory or systemic corticosteroid medication in the last 6 months * smokers are not included in the study
advanced ovarian cancer and sexuality phase 1

Conditions: Ovarian Cancer; Sexual Function

Summary: women with advanced ovarian cancer (aoc) suffer from severe sexual side effects from treatment. the prevalence of the sexual issues is not known. the degree to which these sexual side effects is affected by treatment is also not known, as the literature in this area focuses on post-treatment analysis. specific aim #1 (quantitative phase): to determine the prevalence and types of sexual difficulties using self-report questionnaires in women about to receive treatment for stage iii or iv ovarian cancer at the bcca and over time, and to correlate these symptoms with degree of cancer symptoms, well-being, depressive symptoms, and relationship satisfaction

hypothesis 1a: compared to baseline pre-treatment data, and to existing data for women with early-stage gynaecologic cancer, rates of sexual difficulties will be significantly higher and frequency of sexual intercourse will be significantly lower in women with advanced ovarian cancer. we hypothesize that difficulties specifically in the domains of sexual desire, sexual distress, and genital pain will be the most common types of sexual dysfunction to characterize women with advanced ovarian cancer. hypothesis 1b: we hypothesize that the degree of sexual symptoms will be significantly greater at 3 months and 10 months post-treatment than compared to pre-treatment, and that sexual difficulties may be significantly greater at 3 months post-treatment than at 10-months post-treatment. hypothesis 1c: we hypothesize that degree of sexual difficulty and sexual distress will be significantly correlated with (a) overall well-being; (b) depressive symptoms; and (c) relationship satisfaction. hypothesis 1d: as an exploratory analysis, we will investigate the relationship of ovarian cancer-related variables (i.e., type of treatment, duration of treatment, number of medications), and demographic variables (i.e., age, relationship duration, education) on each of the hypotheses in 1a - 1c.

Eligibility criteria:
inclusion criteria: * women with advanced ovarian cancer (aoc) who have not received treatment yet, but who are seeking treatment at the bc cancer agency. * women must be able to understand english enough to fill out the questionnaire packages. * mastery of written english is required. no translation services will be available for this study. exclusion criteria: * anyone without an aoc diagnosis, who are not seeking treatment at bcca, or who cannot understand enough english to complete the questionnaires will be excluded. * those who do not have a mastery of written english are excluded.

Keywords: advanced ovarian cancer sexual function
hawthorn extract randomized blinded chronic heart failure (herb chf) trial

Conditions: Chronic Heart Failure

Summary: to determine the effect of hawthorn extract 450 mg bid vs. placebo, in addition to standard medical therapy in ambulatory patients with nyha class ii to iv chronic heart failure on submaximal exercise as measured by the 6-minute walk test

see brief summary

Eligibility criteria:
inclusion criteria: * ambulatory individuals 18 years and older who had been diagnosed with chf (nyha functional classes ii-iv) for \> 3 months * left ventricular ejection fraction (lvef) of ≤ 40 percent * receiving indicated standard therapy (if not contraindicated or intolerant for \> 3 months) defined as a diuretic, an ace-inhibitor or an angiotensin receptor blocker (arb) and a beta-blocke * patients with nyha class iii or iv symptoms were also required to receive spironolactone. doses of these drugs had to be stable for ≥ 3 months, except for diuretics, for which ≥ 1 month of stability was required. exclusion criteria: * hemodynamically severe uncorrected primary valvular disease * active myocarditis * hypertrophic cardiomyopathy * restrictive cardiomyopathy * myocardial infarction, stroke, unstable angina, coronary artery bypass graft surgery, valvular surgery, or angioplasty \< 3 months before randomization * symptomatic or sustained ventricular tachycardia not controlled by antiarrhythmic drugs or an implantable cardioverter-defibrillator * any condition other than heart failure that would be expected to limit exercise (e.g., angina, peripheral vascular disease, pulmonary disease, arthritis, or an orthopedic problem severe enough to limit exercise) * nursing mothers, pregnant women and those planning a pregnancy during the study period

Keywords: hawthorn crataegus herbs
precision antibiotic dosing for appendectomy

Conditions: Appendicitis (Diagnosis)

Summary: this research is studying a drug called cefoxitin already approved by the food and drug administration (fda) to reduce the risk of infection after surgery to remove an appendix. researchers are studying a large group of people to continue to learn how best to dose antibiotics. this research will compare the current standard treatment which is a single dose prior to surgery to a new method that includes adding another dose of cefoxitin within 30 minutes of starting the surgery. this study will measure cefoxitin concentrations in blood, fat, and appendix tissue samples to compare the standard dosing method to our new method. this information will help us figure out the right dose of this drug to prevent infection after surgery to remove an appendix.

this interventional, phase 1 study aims to improve surgical site infection (ssi) prevention in patients undergoing appendectomy for uncomplicated appendicitis. despite standard antibiotic prophylaxis, ssi rates remain high, with a pelvic abscess risk of 9.4%. current prophylactic antibiotic regimens may not achieve optimal tissue concentrations, especially in fat and appendix tissue. this study will evaluate the probability of target attainment (pta) of cefoxitin, cefuroxime, and metronidazole in plasma, subcutaneous fat, and appendix tissue. a cohort of 46 adult patients will be randomized to receive standard-of-care antibiotics with or without an additional cefoxitin dose. antibiotic concentrations will be measured in collected blood, fat, and appendix samples. the study's primary objective is to determine whether a supplemental cefoxitin dose improves pta compared to standard prophylaxis. population pharmacokinetic modeling will validate the intervention's effectiveness in optimizing antibiotic exposure and reducing ssi risk. the results may inform future precision antibiotic dosing strategies for appendectomy and other acute care surgeries. primary outcome measure: probability of achieving 50% time above 8 mcg/ml (cefuroxime or cefoxitin) in appendix tissue between intervention and standard care groups. study design: randomized, interventional, phase 1 study enrollment: 46 participants inclusion: adults (\>18 years) undergoing appendectomy for acute appendicitis exclusion: pregnant individuals, prisoners, patients with perforation or abscess this study seeks to improve perioperative antibiotic management, reducing ssi rates while minimizing unnecessary antibiotic exposure and resistance development.

Eligibility criteria:
inclusion criteria: * diagnosis of acute appendicitis and plan to undergo appendectomy at the university of michigan exclusion criteria: * prisoners * patients that are pregnant * patients with perforation or abscess on ct scan

Keywords: cefoxitin appendectomy surgical site infections
clinical significance and prognostic value of prenatal diagnosis of obliteration of the cavum septum pellucidum

Conditions: Fetal Neurodevelopmental Disorder; Cavum Septum Pellucidum

Summary: the aim of this observational study is to evaluate the incidence of the occurrence of additional abnormalities in fetuses diagnosed with cavum septum pellucidum (csp) obliteration performed at second-trimester ultrasound, as well as to analyze the postnatal neurological outcome.

in cases of failure to visualize the csp (obliterated or absent) and additional brain anatomical abnormalities, the feto-neonatal prognosis turns out to be mainly related to the type of associated malformation. it is still debated, however, the prognosis of an absent or isolated obliteration of the spc in the presence of remaining regular brain anatomy for the time. very often, the patient is offered fetal brain mri, which, compared with ultrasonography, appears to be endowed with greater accuracy in identifying any additional associated cerebral animals. in our center, it is a shared custom to routinely offer the patient the option of performing an mri, in all cases of failure to visualize the spc. if obliteration of the csp is confirmed as isolated, normal clinical practice is to perform monthly ultrasound monitoring and a second mri at approximately 30 to 32 weeks, with the aim of ruling out the appearance of further developmental abnormalities. in addition, a specialized pediatric evaluation is usually performed after birth with the aim of following the child developmentally. in a retrospective manner, clinical data of patients followed at our center from 01/01/2024 to 31/05/2021, with a finding of obliteration of the csp at the second trimester, will be considered. of these patients, data from the morphologic ultrasound and concomitant neurosonography and subsequent mri (if performed) will be analyzed, as well as those that emerged during follow-ups performed until the end of pregnancy. for the purpose of assessing the fetal neurological outcome, such patients will be contacted by telephone, the study will be explained to them, and a proposal will be made for a psychiatric examination at the department of child neuropsychiatry for their child. during this visit the child will be administered psycho-aptitude tests routinely used, according to normal clinical practice, in neurodevelopmental assessment, in accordance with the child's age. if the patients do not agree to have their children undergo this visit, only the analysis of the data collected during the visits, performed during pregnancy, will be done.

Eligibility criteria:
inclusion criteria: * pregnant participants with a diagnosis of cavum septum pellucidum obliteration made at second-trimester morphologic ultrasound between 19+0 and 21+6 weeks * age \> or = 18 years at the time of outpatient access * acquisition of informed consent form, from the patient and minor * patients followed at our center exclusion criteria: * none

Keywords: cavum septum pellucidum